Skip to content
CancerIndex

Publication

Therapeutic targeting of IL-17A-driven PTGS2/NLRP3 inflammasome activation in juvenile myelomonocytic leukemia.

Santhosh Kumar Pasupuleti, Baskar Ramdas, Kanaka Sai Ram Padam, Rahul Kanumuri, Lakshmi Reddy Palam, Ramesh Kumar, Tzu-Chieh Ho, Alex G Lee, Wade D Clapp, Cheng-Kui Qu, Elliot Stieglitz, Kai Yang, Reuben Kapur

BloodSep 17, 2026PMID 42233403doi:10.1182/blood.2025032588 PMC13588730Journal ArticlepubmedProvenance
Source
PubMed
Retrieved
Sep 30, 2026
Layer
normalized (units and labels harmonized; values unchanged)
Run
ING-PUBMED-20260930-000001
Published

Abstract

Abstract (excerpt)

Only the opening of the abstract is shown; abstract text may carry publisher copyright.

Juvenile myelomonocytic leukemia (JMML) is an aggressive pediatric myelodysplastic syndrome or myeloproliferative disorder for which hematopoietic stem cell transplantation remains the only curative option; however, outcomes are particularly poor in patients harboring PTPN11 (encodes SHP2…

Read on PubMed

Linked entities

Linked entities (1)

How each link was made (MeSH, dictionary, registry reference, curation…) and whether it has been validated. Candidate links are not counted in entity statistics.

Candidate 1

Curated evidence

Evidence citing this paper (0)

Data not yet available

No curated evidence item cites this publication.